ArticleResearch in pharmaceutical sciences2026
The combination of rosuvastatin and meloxicam enhances the radiotherapy efficacy of MCF7, T-47D, and MDA-MB-231 breast cancer cell lines.
Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Radiotherapy is an essential treatment for breast cancer, but radioresistance remains a major obstacle. Studies suggest that statins and cyclooxygenase-2 (COX-2) inhibitors can enhance radiotherapy, yet few have examined their combined effects on breast cancer radiosensitivity. This study investigates the impact of meloxicam and rosuvastatin pretreatment on the radiosensitivity of MCF-7, T-47D, and MDA-MB-231 breast cancer cell lines. Experimental approach: MCF-7, T-47D, and MDA-MB-231 cells were pretreated with varying concentrations of meloxicam, rosuvastatin, or both. Their response to radiation was evaluated using micronucleus, clonogenic, catalase, and superoxide dismutase (SOD) assays to assess chromosomal damage, cell survival, oxidative stress (via hydrogen peroxide degradation), and SOD antioxidant enzyme activity, respectively. Findings/Results: Pretreatment with combined rosuvastatin (R) and meloxicam (M) at R2+M10 μM, R10+M50 μM, and R20+M100 μM increased genotoxicity and reduced colony formation across all irradiated cell lines compared to radiation alone. R10 μM, R10+M50 μM, and R20+M100 μM decreased catalase activity across irradiated cell lines compared to radiation alone, whereas R2+M10 μM decreased catalase activity significantly only in T-47D cells. Pretreatment with R10 μM, R2+M10 μM, R10+M50 μM, and R20+M100 μM reduced SOD activity in all irradiated cell lines compared to radiation alone. Conclusion and implications: The combination of rosuvastatin and meloxicam at specific concentrations increased the radiation sensitivity of MCF-7, T-47D, and MDA-MB-231 cells. Combined pretreatment with rosuvastatin 10 μM and meloxicam 50 μM notably enhanced genotoxicity while reducing colony formation, catalase activity, and SOD activity compared to radiotherapy alone in MCF-7, T-47D, and MDA-MB-231 cell lines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.